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Patients in the NTI cohort tended to have ‘shorter’ neck. The NTI technique utilized
lesser amount of Thrombin with a trend to a higher success rate and lesser recurrence. The
two patients in the NTI group with recurrent PSA on follow-up imaging study were both
on Coumadin and both PSAs were successfully treated with re-injection of Thrombin. No
serious complications were observed including thromboembolism, limbischemia, aneu-
rysm rupture, or abscess formation.
Conclusion: Femoral pseudoaneurysm closure using the NTI technique is a safe and
efficacious treatment modality. This offers a non-surgical treatment option for PSAs with
morphological features not ideal for the usual STI technique.
NTI
(n  56)
STI
(n  91) P value
Amount of thrombin[IU]
Mean (SD) 994.55 (920) 1501.52 (1384.7) 0.02
Neck length [mm]:
Min; max 0; 2.43 0.13; 3.3
Mean (SD) 0.76 (0.56) 1.06 (0.66) NS
Neck width [mm]:
Min; max 0.1; 2.0 0.1; 2.3
Mean (SD) 0.67 (0.47) 0.78 (0.47) NS
Number of sacs:
1 37 (66.1%) 57 (62.6%)
2 15 (26.8%) 28 (30.8%)
3 4 (7.1%) 6 (6.6%) NS
Success 56 (100%) 87 (96.7%) NS
Recurrence 2 (3.8%) 11 (12.6%) NS
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Background: In the Valentines II trial, the use of second-generation DIOR® paclitaxel
drug-coated balloon (DCB) as adjunct therapy to plain old balloon angioplasty (POBA)
has shown good clinical outcomes in patients with de novo coronary lesions with low rates
of major adverse cardiac events (MACE). We report the quantitative coronary angiog-
raphy (QCA) results of the subset of patients who underwent angiographic follow-up.
Methods: Valentines II trial prospectively enrolled 103 patients with de novo lesions of
50% stenosis who presented with angina and/or documented ischemia on stress testing.
Patients underwent POBA followed by DCB, and in cases of suboptimal angiographic
success additional bail-out stenting was performed. Primary endpoint was MACE at 6-9
months. A subset of patients underwent angiographic follow-up with QCA.
Results: For the study population, MACE, target vessel revascularization and target
lesion revascularization rates were 8.7%, 6.9% and 2.9% respectively. Angiogram was
performed in 35 patients (34%) at mean follow-up of 227  40 days. The QCA results
are shown (Table). Late-luminal loss at follow-up was 0.38  0.39 mm and binary
restenosis was 14.3%.
Conclusion: The result of the Valentines II trial angiographic cohort demonstrates the
efficacy of second generation DIOR® DCB as adjunct to POBA in treating patients with
de novo coronary lesions. This approach achieved low late-luminal loss and binary
restenosis at intermediate-term angiographic follow-up and should be considered for
patients and lesions not suitable for drug-eluting stents.
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Background: The Resolute Integrity zotarolimus-eluting stent utilizes novel continuous
sinusoid technology (CST). With CST, a single cobalt alloy wire is formed into a
repeating sinusoidal pattern, wrapped helically and fused to improve conformability,
provide greater flexibility and ease of delivery without compromising other important stent
design characteristics like radial and longitudinal strength. The objective of the
DELIVER study was to evaluate delivery success as well as in-hospital outcome following
use of the Resolute Integrity stent in an all-comers large patient population.
Methods: DELIVER is a prospective, multicentre, single arm, open-label, observational
study in 163 centers in 33 countries. Patients with coronary artery disease and a lesion of
reference vessel diameter of 2.25 to 4.0 mm were eligible for inclusion. Group 1 received
the Resolute Integrity stent as the first choice of stent treatment and Group 2 were treated
following delivery failure of another stent type. The primary endpoint for the study was
delivery success defined as complete passage of the stent across the target lesion with full
expansion to the desired diameter at the desired location. Other endpoints are in-hospital
clinical outcomes adjudicated by a clinical event committee.
Results: A total of 7740 patients (12165 stents in 10449 lesions) were enrolled between
February 2011 and June 2012. Patients suffered from diabetes mellitus in 34.9% and acute
myocardial infarction 28.4%. Procedure approach was radial in 46.0%, brachial in 0.6% or
femoral in 53.3%. Multiple lesions were treated in 26.9%, pre-dilatation performed in
67.4% and post-dilation in 39.3%. Lesions were de-novo in 94.5% and restenotic in 5.5%.
Type B2/C lesions were treated in 58.8%. Reference diameter pre stent implantation was
2.930.48mm. The primary endpoint delivery success was high with 98.9% [95% CI
98.7-99.1%] in group I and 98.0% [95% CI 89.1-99.9%] in group 2. Adjudicated
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